DUBLIN – Adrenomed AG disclosed Feb. 21 that its first-in-class antibody, adrecizumab, hit the primary safety and tolerability endpoint of a phase II trial in septic shock. The Hennigsdorf, Germany-based company is keeping the efficacy data under wraps for now, however. It did report a trend suggesting that adrecizumab provided a benefit on all-cause mortality vs. placebo.

Infectious disease has been rough going for all comers the past few years, as companies have floundered. Appili Therapeutics Inc.’s CEO, Armand Balboni saw the troubles others encountered with the indication and also saw companies with thin pipelines struggle, but it hasn’t stopped him from forging on.